LunarCrush LLM | creator/twitter::1259520480/posts

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@EyePointPharma](/creator/twitter/EyePointPharma)
"$EYPT announces pivotal Phase X program in diabetic macular edema (#DME): 📅First patient dosing for pivotal Phase X trials anticipated in Q1 2026 🔎New preclinical data suggests multi-MOA targeted approach 🎤Presenting the preclinical data at Eyecelerator at #AAO2025"  
[X Link](https://x.com/EyePointPharma/status/1978194715196703202) [@EyePointPharma](/creator/x/EyePointPharma) 2025-10-14T20:22Z 1469 followers, XXX engagements


"$EYPT announces closing of underwritten public offering of $XXX million of shares of its common stock. Additional details are available here:"  
[X Link](https://x.com/EyePointPharma/status/1979266034990203256) [@EyePointPharma](/creator/x/EyePointPharma) 2025-10-17T19:19Z 1470 followers, XX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@EyePointPharma "$EYPT announces pivotal Phase X program in diabetic macular edema (#DME): 📅First patient dosing for pivotal Phase X trials anticipated in Q1 2026 🔎New preclinical data suggests multi-MOA targeted approach 🎤Presenting the preclinical data at Eyecelerator at #AAO2025"
X Link @EyePointPharma 2025-10-14T20:22Z 1469 followers, XXX engagements

"$EYPT announces closing of underwritten public offering of $XXX million of shares of its common stock. Additional details are available here:"
X Link @EyePointPharma 2025-10-17T19:19Z 1470 followers, XX engagements